Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Brain Neoplasms × gadoterate meglumine × Clear all

Phase

Phase 4 1 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 2 Prostatic Neoplasms 1 Neuroendocrine Tumors 1 Colorectal Neoplasms 1 Breast Neoplasms 1 Brain Neoplasms 1

Interventions

Saline Solution 4 Sugammadex 2 Sodium Chloride 2 Magnetic Resonance Spectroscopy 2 Levetiracetam 2 Fluorescein 2 Dexmedetomidine 2 trastuzumab deruxtecan 1 trastuzumab biosimilar HLX02 1 perampanel 1 pegvisomant 1 gadoterate meglumine 1 gadobenic acid 1 dexketoprofen trometamol 1 clevidipine 1 Trastuzumab 1 Tramadol 1 Sevoflurane 1 Propofol 1 Positron-Emission Tomography 1 Phenylephrine 1 PF-05280014 1 PAVE protocol 2 1 Ontruzant 1 Ogivri 1 Octreotide 1 Morphine 1 Methylphenidate 1 Itraconazole 1 Gadolinium DTPA 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02034708 2016-12-30

REMIND

Guerbet

Phase 4 Completed

279 enrolled 9 charts

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡